Vaxart’s vaccine could sidestep antivector response concerns and has potential to prevent transmission.
An Iran-staged trial shows SpikoGen exceeded the 60% efficacy bar in the primary endpoint of prevention of symptomatic disease.
Eli Lilly’s lebrikizumab in eczema and AbbVie in blood cancers are among other assets reviewed by GlobalData’s Investigative News team.
Biogen's Tofersen did not meet its efficacy results in the Phase III VALOR study for ALS, which reflects the struggle to find treatments for this disease.
There is a number of DMT therapies for AD that are at the last stages of development, with Roche's gantenerumab acquiring BTD status in October.